Open AccessBeyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines
Author(s) -
Jesica Swanstrom,
Usha K. Nivarthi,
Bhumi Patel,
Matthew J. Delacruz,
Boyd Yount,
Douglas G. Widman,
Anna P. Durbin,
Stephen S. Whitehead,
Aravinda M. de Silva,
Ralph S. Baric
Publication year - 2019
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiz109
Subject(s) - dengue virus , dengue vaccine , virology , epitope , flavivirus , dengue fever , serotype , antibody , antibody dependent enhancement , vaccination , neutralizing antibody , virus , biology , epitope mapping , immunology , medicine
Dengue virus is an emerging mosquito-borne flavivirus responsible for considerable morbidity and mortality worldwide. The Division of Intramural Research, National Institute of Allergy and Infectious Diseases of the US National Institutes of Health (NIH) has developed live attenuated vaccines to each of the 4 serotypes of dengue virus (DENV1-4). While overall levels of DENV neutralizing antibodies (nAbs) in humans have been correlated with protection, these correlations vary depending on DENV serotype, prevaccination immunostatus, age, and study site. By combining both the level and molecular specificity of nAbs to each serotype, it may be possible to develop more robust correlates that predict long-term outcome.